Myomo Inc (A:MYO)

Business Focus: Medical Equipment, Supplies & Distribution

Mar 28, 2024 04:05 pm ET
Myomo Appoints Heather Getz to its Board of Directors
Myomo, Inc. (NYSE American: MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced the appointment of Heather Getz as a Class II director and chair of its audit committee effective March 26, 2024, to serve until the 2025 annual meeting of stockholders. With this appointment, Myomo has seven directors.
Mar 07, 2024 04:05 pm ET
Myomo Reports Fourth Quarter and Full Year 2023 Financial Results
Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced financial results for the three months and year ended December 31, 2023.
Mar 01, 2024 08:00 am ET
CMS Posts Final Medicare DMEPOS Fee Schedule Rate for the MyoPro®
Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that on February 29, 2024, the Centers for Medicare & Medicaid Services (CMS) posted the final Medicare Durable Medical Equipment, Prosthetics, Orthotics, and Supplies (DMEPOS) fee schedule payment rates for the MyoPro®.
Feb 29, 2024 04:05 pm ET
Myomo to Report Fourth Quarter Financial Results on March 7, 2024
Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that it will report financial results for the fourth quarter and fiscal year ended December 31, 2023 on March 7, 2024.
Jan 19, 2024 04:05 pm ET
Myomo Announces Closing of $6 Million Registered Direct Offering of Common Stock Priced At-the-Market
Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that it has closed its previously announced registered direct offering of its common stock, priced at-the-market with certain new and existing institutional investors as well as certain insiders of the Company, for the purchase and sale of 1,578,948 shares of common stock (or common stock equivalents in lieu thereof) at a purchase price of $3.80 per share, which was t
Jan 17, 2024 08:05 am ET
Myomo Announces $6 Million Registered Direct Offering of Common Stock Priced At-the-Market
Myomo, Inc. (NYSE American: MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that it has entered into securities purchase agreements with certain new and existing institutional investors as well as certain insiders of the Company for the purchase and sale of 1,578,948 shares of common stock (or common stock equivalents in lieu thereof) at a purchase price of $3.80 per share, which was the closing price of the Company’s common stock traded on t
Jan 17, 2024 08:00 am ET
Myomo Reports Preliminary Fourth Quarter Revenue and Backlog
Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced preliminary revenue and operating metrics for the fourth quarter of 2023.
Dec 18, 2023 08:31 am ET
Thinking about buying stock in iCoreConnect, C4 Therapeutics, SoundHound AI, Myomo, or Algoma Steel Group?
NEW YORK, Dec. 18, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ICCT, CCCC, SOUN, MYO, and ASTL.
Nov 07, 2023 04:05 pm ET
Myomo Reports Third Quarter 2023 Financial Results Featuring Record Product Revenue and Authorizations
Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced financial results for the three and nine months ended September 30, 2023.
Nov 06, 2023 08:30 am ET
CMS Posts Proposed Medicare DMEPOS Fee Schedule Rate for the MyoPro® for Review at the Upcoming HCPCS Public Meeting
Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that the Centers for Medicare & Medicaid Services (CMS) posted a proposed Medicare Durable Medical Equipment, Prosthetics, Orthotics, and Supplies (DMEPOS) fee schedule payment rate for the MyoPro® to be discussed at CMS’ bi-annual Healthcare Common Procedure Coding System (HCPCS) Public Meeting, scheduled for November 29, 2023.
Nov 02, 2023 10:08 am ET
Myomo Announces that CMS has Classified the MyoPro Orthosis Under the Brace Benefit Category
Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that the Centers for Medicare & Medicaid Services (CMS) published a final rule classifying the MyoPro under the brace benefit category. Braces are paid on a lump sum basis under the Social Security Act. The finalization of MyoPro’s classification as a brace paid on a lump sum basis, rather than on a capped rental basis, brings Medicare payment methodology in line with
Oct 31, 2023 04:05 pm ET
Myomo to Report Third Quarter Financial Results on November 7, 2023
Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that it will report financial results for the three and nine months ended September 30, 2023 on November 7, 2023.
Aug 29, 2023 04:05 pm ET
Myomo Announces Closing of $4.4 Million Public Offering
Myomo, Inc. (NYSE American: MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced the closing of its previously announced "reasonable best efforts" public offering of 7,333,334 shares of common stock (or common stock equivalents in lieu thereof) at a public offering price of $0.60 per share for aggregate gross proceeds of approximately $4.4 million, before deducting placement agent fees and other offering expenses.
Aug 25, 2023 07:00 am ET
Myomo Announces Pricing of $4.4 Million Public Offering
Myomo, Inc. (NYSE American: MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced the pricing of its "reasonable best efforts" public offering of 7,333,334 shares of common stock (or common stock equivalents in lieu thereof) at a public offering price of $0.60 per share for aggregate gross proceeds of approximately $4.4 million, before deducting placement agent fees and other offering expenses.
Aug 24, 2023 04:15 pm ET
Myomo, Inc. Announces Proposed Public Offering
Myomo, Inc. (NYSE American: MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that it intends to offer and sell shares of its common stock (or common stock equivalents in lieu thereof) in a “reasonable best efforts” public offering. All of the securities to be sold in the offering are to be offered by Myomo. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to
Aug 24, 2023 04:05 pm ET
 Myomo Receives Medicare Part B Reimbursement for First MyoPro® Claims
Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that it has received payments for two claims submitted for MyoPro® arm braces provided to Medicare fee-for-service beneficiaries.
Aug 21, 2023 04:05 pm ET
Myomo Announces Two German Social Court Rulings Ordering MyoPro® Reimbursement
Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that two insurers in Germany have been ordered to cover the MyoPro® as a result of successful appeals before two regional social courts in Germany. In each case, the courts confirmed that the MyoPro powered arm orthosis is an orthopedic aid that serves to directly compensate for disabilities. As a result of these rulings, BARMER, Germany’s second-largest statutory hea
Aug 09, 2023 04:05 pm ET
Myomo Reports Second Quarter 2023 Financial Results Featuring Year Over Year Growth in Revenue and Operating Metrics
Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced financial results for the three and six months ended June 30, 2023.
Aug 02, 2023 04:05 pm ET
Myomo to Report Second Quarter Financial Results on August 9, 2023
Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that it will report financial results for the three and six months ended June 30, 2023 on August 9, 2023.
Jul 03, 2023 08:30 am ET
Centers for Medicare and Medicaid Services Accepts Myomo’s Application to Classify the MyoPro® as a Brace
Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, announces that its request to the Centers for Medicare and Medicaid Services (“CMS”) to classify the Company’s MyoPro as a brace has been published for public comment.
Jun 14, 2023 04:05 pm ET
Myomo To Participate in the Maxim Group Virtual Healthcare Conference Hosted by M-Vest
Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, announces that management will be participating in the Maxim Group Virtual Healthcare Conference hosted by M-Vest on Tuesday June 20, 2023. Paul Gudonis, Myomo’s chairman and chief executive officer, and David Henry, Myomo’s chief financial officer, will be participating in a fireside chat hosted by Maxim Group Executive Managing Director of Research Anthony V. Vendetti beginning at
May 10, 2023 04:05 pm ET
Myomo Reports First Quarter 2023 Financial Results Featuring 20% Year Over Year Increase in Product Revenue
Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced financial results for the three months ended March 31, 2023.
May 03, 2023 04:05 pm ET
Myomo to Report First Quarter Financial Results on May 10, 2023
Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that it will report financial results for the three months ended March 31, 2023 on May 10, 2023.
Apr 10, 2023 08:30 am ET
Myomo Receives Technology License Fee Payment from China Joint Venture Company
Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, announces receipt of the final portion of the initial license fee under the Technology License Agreement with its joint venture company in China, Jiangxi Myomo Medical Assistive Appliance Co. Ltd. (the “JV Company”).
Mar 15, 2023 08:30 am ET
Myomo Makes NYSE American Section 610(b) Public Announcement
Myomo, Inc. (NYSE American: MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that, as previously disclosed in its Annual Report on Form 10-K for the year ended December 31, 2022 filed on March 13, 2023 with the Securities and Exchange Commission, the audited financial statements for the year ended December 31, 2022 included in the 10-K contained an audit opinion from its independent registered public accounting firm, which included a going con
Mar 13, 2023 08:30 am ET
Myomo Reports Fourth Quarter and Full Year 2022 Financial Results
Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced financial results for the three months and full year ended December, 31, 2022.
Mar 07, 2023 10:12 am ET
Myomo to Report Fourth Quarter Financial Results on March 13, 2023
Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that it will report financial results for the three months and year ended December 31, 2022 on March 13, 2023 before the opening of the market.
Mar 06, 2023 04:05 pm ET
Myomo To Participate in the 35th Annual Roth Conference
Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, announces that management will presenting at the 35th Annual Roth Conference, March 13-14, 2023 at The Ritz-Carlton, Dana Point, Calif. David Henry, Myomo’s chief financial officer will participate in a “Fireside Chat” on Monday, March 13th at 1:30 p.m. PT and will be available for one-on-one meetings throughout the conference. A live webcast of the prese
Mar 06, 2023 04:05 pm ET
Myomo to Report Third Quarter Financial Results on March 13, 2023
Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that it will report financial results for the three months and year ended December 31, 2022 on March 13, 2023 before the opening of the market.
Feb 06, 2023 04:05 pm ET
MyoPro Approved in Australia by National Disability Insurance Scheme
Myomo, Inc. (NYSE American: MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, announced that for the first time, the National Disability Insurance Scheme (NDIS) in Australia approved a MyoPro for a patient with a paralyzed arm. The NDIS aids over 500,000 Australians with disabilities through reimbursement for necessary services and support.
Jan 30, 2023 04:05 pm ET
Myomo Appoints Yitzchak Jacobovitz to its Board of Directors
Myomo, Inc. (NYSE American: MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced the appointment of Yitzchak Jacobovitz as a Class II director effective January 27, 2023, to serve until the 2025 annual meeting of stockholders. With this appointment, Myomo has six directors.
Jan 17, 2023 04:05 pm ET
Myomo Announces Closing of $6.5 Million Upsized Public Offering
Myomo, Inc. (NYSE American: MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced the closing of its previously announced "best efforts" public offering of 20,000,000 shares of common stock (or common stock equivalents in lieu thereof) at a public offering price of $0.325 per share for aggregate gross proceeds of approximately $6.5 million, before deducting placement agent fees and other offering expenses.
Jan 12, 2023 08:30 am ET
Myomo Announces Pricing of $6.5 Million Upsized Public Offering
Myomo, Inc. (NYSE American: MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced the pricing of its "best efforts" public offering of 20,000,000 shares of common stock (or common stock equivalents in lieu thereof) at a public offering price of $0.325 per share for aggregate gross proceeds of approximately $6.5 million, before deducting placement agent fees and other offering expenses.
Jan 10, 2023 04:17 pm ET
Myomo Announces Initiative to Reduce Cash Burn
Myomo, Inc. (NYSE American: MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced a reduction in force for the purpose of improving operating efficiency in its direct billing channel and reduce its cash burn. The action today involved the elimination of approximately 12% of its workforce, impacting employees in its call center and administrative functions. This action and other cost reductions being undertaken by the Company are expected to save in
Dec 07, 2022 05:00 pm ET
Myomo Provides Update on Progress to Obtain Medicare Part B Reimbursement for MyoPro
Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today reported progress and next steps in the process to obtain Medicare Part B reimbursement for the MyoPro® as a brace from the Centers for Medicare & Medicaid Services (CMS).
Dec 05, 2022 08:30 am ET
Ruling by German Social Court Supports MyoPro Reimbursement by Nation’s Statutory Health Insurance System
Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that in an appeal before the Berlin-Brandenburg Regional Social Court (L 9 KR 210/21), the court confirmed that the MyoPro powered whole-arm orthosis is an orthopedic aid that serves to directly compensate for disabilities. As a result of this ruling, the third-largest German health insurance company, DAK, has been ordered to cover the costs for the MyoPro for the pla
Nov 10, 2022 04:05 pm ET
Myomo Reports Third Quarter 2022 Financial Results Featuring Strong Authorizations and Orders and Record Backlog
Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced financial results for the three and nine months ended September 30, 2022.
Nov 03, 2022 04:05 pm ET
Myomo to Report Third Quarter Financial Results on November 10, 2022
Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that it will report financial results for the three and nine months ended September 30, 2022 on November 10, 2022, after the market close.
Oct 05, 2022 04:30 pm ET
Myomo To Present at the MicroCap Rodeo Presents The Windy City Roundup 2022
BOSTON, MA / ACCESSWIRE / October 5, 2022 / Myomo, Inc. (NYSE American:MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that Paul Gudonis, Myomo's chairman and chief executive officer, will present at the Microcap Rodeo presents The Windy City Roundup 2022 conference, which is being held live, in-person on October 12th - 13th, 2022.
Sep 27, 2022 09:05 am ET
60+ Companies to Present at the 2nd Annual MicroCap Rodeo - Windy City Roundup Conference on October 12th - 13th, 2022 in Chicago
RALEIGH, NC / ACCESSWIRE / September 27, 2022 / The 2nd Annual MicroCap Rodeo Conference is going on the road and will take place at the Swissotel in Chicago on October 12th - 13th, 2022, where 60+ SmallCap, MicroCap and NanoCap public companies will be presenting to a global investor audience.
Sep 07, 2022 08:30 am ET
Myomo to Present at the H.C. Wainwright 24th Annual Global Investment Conference
Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that management will present at the H.C. Wainwright 24th Annual Global Investment Conference. The Conference is being held September 12 – 14, both virtually and in New York City. Paul Gudonis, chief executive officer, and David Henry, chief financial officer, will participate virtually. A webcast of the presentation will be available on-demand beginning Sep
Aug 30, 2022 08:30 am ET
Myomo Receives Order from the Louis Stokes Cleveland VA Medical Center to Support MyoPro Clinical Trial
Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced receipt of a $120,000 order for MyoPro® units from Cleveland’s Louis Stokes Veterans Administration (“VA”) Medical Center. The units will be used in an investigator-initiated, randomized clinical trial led by Svetlana Pundik, M.D., Assistant Professor, Department of Neurology, Case Western Reserve University School of Medicine and Director, Brain Plasticity
Aug 03, 2022 04:05 pm ET
Myomo Reports Second Quarter 2022 Financial Results and Record Number of Patient Pipeline Additions
Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced financial results for the three and six months ended June 30, 2022.
Jul 27, 2022 04:15 pm ET
Myomo to Report Second Quarter Financial Results on August 3, 2022
Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that it will report financial results for the three and six months ended June 30, 2022 on August 3, 2022, after the market close.
Jul 07, 2022 04:05 pm ET
Myomo Announces Second Quarter Preliminary Revenue and Record Pipeline Additions
Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, announces preliminary second quarter revenue and provides an update on its pipeline entering the third quarter.
Jun 14, 2022 02:45 pm ET
Sidoti's Summer Small Cap Virtual Conference
NEW YORK, NY / ACCESSWIRE / June 14, 2022 / Sidoti & Company, LLC has released the presentation schedule and weblinks for its two-day Summer Small Cap Virtual Conference taking place Wednesday and Thursday, June 15th-16th, 2022. The links can also be found at www.sidoticonference.com/events.
Jun 09, 2022 04:05 pm ET
Myomo To Present at the Sidoti Summer Small Cap Virtual Investor Conference
Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that Paul Gudonis, Myomo’s chairman and chief executive officer, and David Henry, Myomo’s chief financial officer, will present and provide a business update at the Sidoti Summer Small Cap Conference, which is being held virtually from June 15 to June 16, 2022.
May 11, 2022 04:05 pm ET
Myomo Reports First Quarter 2022 Financial Results
Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced financial results for the three months ended March 31, 2022.
May 04, 2022 04:15 pm ET
Myomo to Report First Quarter Financial Results on May 11, 2022
Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that it will report financial results for the three months ended March 31, 2022 on May 11, 2022 after the market close.
Apr 04, 2022 04:15 pm ET
Myomo Reports Progress with China Joint Venture, Receives Partial Payment of Technology License Fee
Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, provides an update on the status of its joint venture (“JV”) in China and the associated impact on first quarter 2022 revenue. As of March 31, 2022, a portion of the technology license fee from the JV Company, Jiangxi Myomo Medical Assistive Appliance Co. Ltd., has been paid. The Company received $1.0 million of the total $2.7 million license fee during March, which will be accounted
Mar 09, 2022 04:15 pm ET
Myomo To Participate in Two March Investor Conferences
Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, announces that management will participate in two investor conferences during March:
Mar 09, 2022 04:05 pm ET
Myomo Reports Fourth Quarter and Full Year 2021 Financial Results
Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced financial results for the three months and year ended December 31, 2021.
Mar 02, 2022 04:15 pm ET
Myomo to Report Fourth Quarter and Full Year 2021 Financial Results on March 9, 2022
Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that it will report financial results for the three months and fiscal year ended December 31, 2021 on March 9, 2022 after the market close.
Feb 17, 2022 04:15 pm ET
Myomo Strengthens Intellectual Property Portfolio With Receipt of Key Patent in Japan
Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, announces the granting of patent number 6998478 titled “Powered Orthotic Device and Method of Using Same” by the Japanese Patent Office.
Feb 14, 2022 08:30 am ET
Independent Research with Myomo’s MyoPro® Shows Clinically Significant Gains in Motor Function in Individuals with Chronic Moderate-to-Severe Arm Weakness
Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, announces that new research measuring the benefits of the Company’s MyoPro myoelectric orthosis found “statistically significant improvements” in a number of motor function measurements. The research study, titled “Myoelectric Arm Orthosis in Motor Learning-Based Therapy for Chronic Deficits After Stroke and Traumatic Brain Injury,” was funded by the U.S. Army Medical Research Acquis
Jan 18, 2022 07:30 am ET
Sidoti Winter Virtual Small Cap Investor Conference
NEW YORK, NY / ACCESSWIRE / January 18, 2022 / Sidoti & Company, LLC has released the presentation schedule and weblinks for its two-day January Small Cap Virtual Conference taking place Wednesday and Thursday, December 19th-20th, 2022. The links can also be found at www.sidoticonference.com/events.
Jan 13, 2022 04:30 pm ET
Myomo to Present at the Sidoti Winter Small Cap Conference
Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that Paul Gudonis, Myomo’s chairman and chief executive officer, and David Henry, Myomo’s chief financial officer, will present at the Sidoti Winter Small Cap Conference, which is being held virtually from January 19 to January 20, 2022.
Jan 10, 2022 08:30 am ET
Myomo Provides Update on MyoPro® Insurance Reimbursement
Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today provided an update on reimbursement for its MyoPro device by a large private payer that was denying pre-authorized claims after delivery of devices to patients. For the three and nine months ended September 30, 2021, revenue from patients insured by this payer represented 32% and 30% of total revenues, respectively.
Jan 06, 2022 04:05 pm ET
Myomo Announces MyoPro® 2+
Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced the availability of MyoPro 2+, an enhanced version of its popular MyoPro powered brace. Deliveries to patients will begin this month.
Jan 05, 2022 04:05 pm ET
Myomo Amends China Joint Venture Agreement, Executes Technology and Trademark License Agreement
Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper limb paralysis, announces the entry into an amended and restated joint venture agreement (the “Amended JV Agreement”) with Beijing Ryzur Medical Investment Co., Ltd. (“Ryzur Medical”) and Wuxi Chinaleaf Rehabilitation Industry Equity Investment Fund (“Chinaleaf”), and the signing of a Technology License Agreement and a Trademark License Agreement with Jiangxi Myomo Medical Assistive Appliance Co., L
Nov 10, 2021 04:05 pm ET
Myomo Third Quarter 2021 Financial Results Feature Record Revenue
Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced financial results for the three and nine months ended September 30, 2021.
Nov 03, 2021 04:05 pm ET
Myomo to Report Third Quarter 2021 Financial Results on November 10, 2021
Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that it will report financial results for the three and nine months ended September 30, 2021 on November 10, 2021 after the market close.
Oct 15, 2021 09:15 am ET
Myomo, Inc. Announces Agreements for Exercise of 2020 Investor Warrants
Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced it has entered into agreements with certain of its holders of its existing 2020 investor warrants exercisable for 1,015,798 shares of its common stock, in the aggregate, pursuant to which such holders agreed to exercise their warrants for cash at an exercise price of $5.00 per share. The aggregate gross proceeds from the exercise of the existing warrants is expected t
Oct 04, 2021 04:30 pm ET
36 of the Best Ideas Companies to Present at the Fall Harvest - Best Ideas from the Buy-Side Virtual Investor Conference on October 5th - 8th, 2021
RALEIGH, NC / ACCESSWIRE / October 4, 2021 / The Fall Harvest - Best Ideas from the Buy-Side will take place on October 5th - 8th, 2021, where 36 SmallCap, MicroCap and NanoCap public companies will be presenting via virtual webcast to a global investor audience.
Sep 28, 2021 04:30 pm ET
Myomo, Inc. to Present at Fall Harvest - Best Ideas from the Buy-Side on October 5th
BOSTON, MA / ACCESSWIRE / September 28, 2021 / Myomo, Inc. (NYSE American:MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that Paul Gudonis, Myomo's chairman and chief executive officer, and David Henry, Myomo's chief financial officer, will present at the Fall Harvest - Best Ideas From the Buy-Side conference, which is being held virtually from October 5 - 8, 2021.
Sep 07, 2021 04:30 pm ET
Myomo, Inc. Announces Granting of Patents in China and Hong Kong
Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced the granting of patents in China and Hong Kong covering the Company’s most advanced products. Patent number ZL201680032072 was issued in China and patent number 1251447B was issued in Hong Kong. The patents are titled “Powered Orthotic Device and Method of Using Same,” which cover a powered orthotic device that supports movement of a user’s arm about the elbow and a u
Sep 02, 2021 04:30 pm ET
Myomo, Inc. Announces Participation in Three September Investment Conferences
Myomo, Inc. (NYSE American:MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that Paul Gudonis, Myomo’s chairman and chief executive officer, and David Henry, Myomo’s chief financial officer, will participate in three investment conferences in September. They are:
Aug 09, 2021 04:05 pm ET
Myomo Second Quarter 2021 Financial Results Feature Significant Increases in Revenue and Gross Margin, Record Insurance Authorizations and Orders
Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced financial results for the three and six months ended June 30, 2021.
Aug 02, 2021 04:05 pm ET
Myomo to Report Second Quarter 2021 Financial Results on August 9, 2021
Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that it will report financial results for the three and six months ended June 30, 2021 on August 9, 2021 after the market close.
Jul 27, 2021 08:30 am ET
Myomo Receives Accreditation from HQAA
Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that the Healthcare Quality Association on Accreditation (HQAA) has certified Myomo meets the accreditation requirements under the Social Security Act and federal regulations. Accreditation is a program in which trained external peer reviewers evaluate a healthcare organization's compliance and compare it with pre-established performance standards.
Jul 23, 2021 04:05 pm ET
Myomo, Inc. Announces Participation in A.G.P.’s Virtual MedTech Summer Conference on July 29, 2021
Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that management will participate in A.G.P.’s Virtual MedTech Summer Conference on Thursday, July 29, 2021.
Jun 28, 2021 08:30 am ET
Myomo, Inc. Stock Added to Russell Microcap® Index
Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that its stock will be added to the Russell Microcap® Index at the opening of trading today.
Jun 22, 2021 04:45 pm ET
Sidoti Summer Virtual Small-Cap Conference
Presentation Times and Weblinks Released for Approximately 70 Presenting Companies
Jun 16, 2021 04:05 pm ET
Myomo to Present at Sidoti Virtual Investor Conference on June 23, 2021
Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that Paul R. Gudonis, Chief Executive Officer, and David Henry, Chief Financial Officer, will present a corporate overview of the company at the Sidoti Virtual Investor Conference on Wednesday, June 23, 2021, at 10:45 a.m. Eastern time.
Jun 14, 2021 04:05 pm ET
Myomo Shareholders Elect Dr. Milton Morris as Director
Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that its shareholders, at its meeting on June 9, 2021, elected Milton Morris, PhD, as Director. Dr. Morris was elected to serve as a Class I director, with an initial term of three years until the 2024 annual meeting of stockholders.
Jun 08, 2021 08:05 am ET
Myomo Provides Update on CMS Discussions
Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today provided an update regarding its application for a Healthcare Common Procedure Coding System (“HCPCS”) Level II code change and benefit category redetermination for HCPCS codes L8701 and L8702 submitted in January 2021. The Centers for Medicare & Medicaid Services (“CMS”) proposed several changes to the benefit category determination process in its proposed rule (the “Proposed
May 27, 2021 07:15 pm ET
35 of the Best Ideas Companies to Present at the Summer Solstice - Best Ideas from the Buy-Side Virtual Investor Conference on June 1-4, 2021
RALEIGH, NC / ACCESSWIRE / May 27, 2021 / The Summer Solstice - Best Ideas from the Buy-Side will take place on June 1-4, 2021, where 35 SmallCap, MicroCap and NanoCap public companies will be presenting via virtual webcast to a global investor audience.
May 27, 2021 07:15 pm ET
35 of the Best Ideas Companies to Present at the Summer Solstice - Best Ideas from the Buy-Side Virtual Investor Conference on June 1-4, 2021
RALEIGH, NC / ACCESSWIRE / May 27, 2021 / The Summer Solstice - Best Ideas from the Buy-Side will take place on June 1-4, 2021, where 35 SmallCap, MicroCap and NanoCap public companies will be presenting via virtual webcast to a global investor audience.
May 27, 2021 04:05 pm ET
Myomo to Present at the Summer Solstice - Best Ideas From the Buy Side Conference
Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that CEO Paul R. Gudonis and CFO David Henry will present at the Summer Solstice – Best Ideas From the Buy Side Conference on June 1, 2021 at 2:30 p.m. Eastern time. The conference is sponsored by the Microcap Rodeo and will be held virtually June 1-4, 2021.
May 05, 2021 04:05 pm ET
Myomo Reports First Quarter 2021 Financial Results
Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced financial results for the three months ended March 31, 2021.
Apr 27, 2021 04:05 pm ET
Myomo to Report First Quarter 2021 Financial Results on May 5, 2021
Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that it will report financial results for the three months ended March 31, 2021 on May 5, 2021 after the market close.
Apr 01, 2021 08:05 am ET
Myomo Participates in Ground-breaking Brain-computer Interface Trial
Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that Thomas Jefferson University of Philadelphia has successfully completed the first phase of clinical trials using sensors imbedded in the brain to control a MyoPro powered brace worn by a stroke patient.
Mar 10, 2021 04:05 pm ET
Myomo Reports Fourth Quarter and Full Year 2020 Financial Results
Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced financial results for the three months and year ended December 31, 2020.
Mar 04, 2021 04:20 pm ET
Myomo to Participate in Three Investment Conferences During the Month of March
Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that Paul R. Gudonis, Myomo’s CEO, and David Henry, Myomo’s CFO will participate in three virtual investment conferences during the month of March, as follows:
Mar 04, 2021 04:15 pm ET
Myomo to Report Fourth Quarter and Full Year 2020 Financial Results on March 10, 2021
Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that it will report financial results for the three months and year ended December 31, 2020 on March 10, 2021 after the market close.
Feb 16, 2021 08:30 am ET
Germany's Largest Statutory Health Insurance Company Approves MyoPro
Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced Techniker Krankenkasse (TK), Germany's largest Statutory Health Insurance (SHI) company, now approves reimbursement of MyoPro on a case-by-case basis. TK covers over 10 Million insured lives and joins the ranks of other major German health insurance providers including BARMER, IKK Classic, regional AOK insurances and several BKK insurances which collectively cover 28
Feb 12, 2021 04:05 pm ET
Myomo to Present at the Winter Wonderland – Best Ideas from the Buy-side Conference
Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that management will present at the Winter Wonderland – Best Ideas from the Buy-side Conference. The conference is being held virtually on February 16th through February 19th. Myomo’s presentation is scheduled for February 16th at 10:00 a.m. Eastern time and may be accessed at this
Jan 26, 2021 06:30 am ET
Myomo® Forms Joint Venture to Manufacture and Sell the Company’s Products in China
Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper limb paralysis, announces the signing of a definitive agreement (the “JV Agreement”) with Beijing Ryzur Medical Investment Co., Ltd. (“Ryzur Medical”) to form a joint venture (the “JV”) to manufacture and sell the Company’s current and future products in greater China, including Hong Kong, Macau and Taiwan.
Jan 11, 2021 06:00 am ET
Myomo Reports Preliminary Fourth Quarter and Full Year 2020 Results
Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced preliminary financial and operational results for the fourth quarter and fiscal year ended December 31, 2020. In particular, Myomo expects revenue for the three months ended December 31, 2020 to more than double compared with the fourth quarter ended December 31, 2019, and also expects quarterly cash utilization to be the lowest since it became a publicly traded compa
Jan 05, 2021 04:05 pm ET
Myomo to Present H.C. Wainwright Virtual BioConnect 2021 Conference
Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that Paul Gudonis, the Company’s chief executive officer, and David Henry, chief financial officer, will present at the H.C. Wainwright Virtual BioConnect 2021 Conference being held January 11-14, 2021. The presentation can be accessed at the following
Nov 19, 2020 06:45 am ET
Sidoti Virtual Microcap Investor Conference
NEW YORK, NY / ACCESSWIRE / November 19, 2020 / Sidoti & Company, LLC proudly releases the presentation schedule, with weblink click-throughs, for today's Virtual Microcap Investor Conference.
Nov 18, 2020 09:03 am ET
Myomo to Present at Sidoti & Company Virtual Microcap Conference
Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that management will be presenting at the Sidoti & Company Virtual Microcap Conference on Thursday, November 19, 2020 at 1:45 p.m. Eastern Time.
Nov 16, 2020 08:30 am ET
Myomo Introduces MyoGames™
Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company offering increased functionality for individuals suffering from neurological disorders and upper-limb paralysis, announced today the availability of MyoGames by Lusio, a video game platform designed to augment training and rehabilitation for MyoPro users, while being fun. MyoGames enables users to play video games by actively engaging their paralyzed or weakened arm or hand with the MyoPro. The first game, basketball, is available immediately with other titles to follow.
Nov 10, 2020 04:05 pm ET
Myomo Third Quarter Financial Results Feature Record Revenue of $1.9 Million, up 218% Over the Prior Year
Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced financial results for the three and nine months ended September 30, 2020.
Nov 03, 2020 08:30 am ET
Myomo to Report Third Quarter Financial Results on November 10, 2020
Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper limb paralysis, today announced that it will report financial results for the third quarter ended September 30, 2020 on Tuesday, November 10, 2020 after the market close.
Nov 02, 2020 08:30 am ET
Myomo Appoints Dr. Harry Kovelman as Chief Medical Officer
Myomo, Inc. (NYSE American:MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that Harry Kovelman, MD, is joining the Company as its Chief Medical Officer, effective November 2. In this role, Dr. Kovelman will oversee Myomo’s patient advocacy organization, which helps ensure MyoPro patients’ clinical qualification for the brace and pursues insurance coverage. At Myomo, he will work closely with commercial and government payer organizations to co
Oct 08, 2020 03:30 pm ET
The MicroCap Rodeo Best Ideas Bowl 2020; October 13-16, 2020
NEW YORK, NY / ACCESSWIRE / October 8, 2020 / The MicroCap Rodeo continues this year with its first virtual event set for October 13-16, 2020. This year' "Best Ideas" conference focuses solely on 25 public companies recommended by institutional investors and qualified individual investors. The event will feature 2 days of company presentations followed by 2 days of pre-scheduled 1-1's.
Oct 07, 2020 04:30 pm ET
Myomo to Present at the MicroCap Rodeo Best Ideas Bowl on October 13, 2020
CAMBRIDGE, MA / ACCESSWIRE / October 7, 2020 / Myomo, Inc. (NYSE American:MYO), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, has been invited to present at the MicroCap Rodeo Best Ideas Bowl, which is being held virtually on October 13th - 16th, 2020.
Sep 15, 2020 04:05 pm ET
Myomo Certified as Medicare Provider
Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that the Centers for Medicare & Medicaid Services under the U.S. Department of Health and Human Services has authorized the Company to be a Medicare Provider. Myomo is now included in the Medicare Supplier Directory at Medicare.gov, and this designation enables Myomo to bill Medicare directly when it delivers its MyoPro powered orthosis in 39 states plus D.C. The Comp
Sep 10, 2020 08:30 am ET
Myomo® to Present at the H.C. Wainwright Virtual 22nd Annual Global Investment Conference
Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that its management is scheduled to present at the H.C. Wainwright 22nd Annual Global Investment Conference to be held virtually on September 14-16, 2020. Paul Gudonis, chief executive officer and David Henry, chief financial officer of Myomo will present a corporate overview of the Company on Tuesday, September 15, at 4:30 p.m. Eastern time.
Aug 31, 2020 05:00 pm ET
LD Micro - 360 Companies - Set to Present this Week
LOS ANGELES, CA / ACCESSWIRE / August 31, 2020 / LD Micro today announced the final list of companies slated to present at the upcoming LD 500, taking place September 1st-4th, 2020, exclusively online.
Aug 26, 2020 04:05 pm ET
Myomo, Inc. to Present at The LD 500 Virtual Conference
LOS ANGELES, CA / ACCESSWIRE / August 26, 2020 / Myomo, Inc. (NYSE American:MYO), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis today announced that it will be presenting at the LD 500 investor conference on Wednesday, September 2, 2020 at 11:00 a.m. EDT. Chairman and Chief Executive Officer Paul Gudonis and Chief Financial Officer David Henry will be presenting to a live virtual audience.
Aug 26, 2020 06:00 am ET
Myomo® Extends and Strengthens its Global MyoPro™ Patent Portfolio
Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced additional intellectual property protection with the issuance of new patents in the U.S. and Europe related to MyoPro™, its unique wearable robotic brace for arm and hand paralysis.
Aug 20, 2020 06:00 am ET
Myomo® Receives First Australian Insurance Authorization for MyoPro™
Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that a Myomo-trained Orthotic & Prosthetic (“O&P”) practice in Australia has received its first insurance authorization to fit a patient with a custom MyoPro device. This is the first authorization following Myomo’s entry into Australia as part of its international expansion initiative.
Aug 10, 2020 04:05 pm ET
Myomo Reports 2020 Second Quarter Financial Results
Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced financial results for the three and six months ended June 30, 2020.
Aug 05, 2020 09:00 am ET
LD Micro - Announces Preliminary List of Presenters for the LD 500
LOS ANGELES, CA / ACCESSWIRE / August 5, 2020 / LD Micro today announced the initial list of companies slated to present at the upcoming LD 500, taking place September 1st-4th, 2020, exclusively online.
Aug 03, 2020 04:05 pm ET
Myomo to Report Second Quarter Financial Results on August 10, 2020
Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper limb paralysis, today announced that it will report financial results for the second quarter ended June 30, 2020 on Monday, August 10, 2020 after the market close.
Jul 09, 2020 09:31 am ET
Thinking about buying stock in Infinity Pharmaceuticals, Qudian Inc, Myomo Inc, Plug Power, or Sunrun Inc?
NEW YORK, July 9, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for INFI, QD, MYO, PLUG, and RUN.
Jul 09, 2020 06:00 am ET
Myomo® Launches MyoCare™
Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced the launch of MyoCare™, a new program that provides enhanced support to first-year users of the Company’s MyoPro® powered brace in order to maximize the benefits they receive from the device.
Jul 06, 2020 06:00 am ET
Research Finds MyoPro® Delivers Meaningful Improvements in Motor Function for Brain Injury Patient
The Case Report in the Journal of Rehabilitation and Assistive Technologies Engineering (RATE), a peer-reviewed interdisciplinary journal, studied a 42-year-old female, 29.5 years post-traumatic brain injury with diminished motor control/coordination and learned nonuse of the right arm. The research consisted of 9 weeks of in-clinic training followed by 9 weeks of at-home use. It was funded by the U.S. Department of Defense through an award to Dr. Stefania Fatone at the Northwestern University Feinberg School of Medicine in Chicago and conducted by a research team at the Louis Stokes Cleveland
Jun 22, 2020 06:00 am ET
Myomo Resumes Fitting MyoPro Patients and Deliveries as States Begin to Re-Open after COVID-19 Shutdowns
Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced it has resumed in-person patient visits for casting, fitting and delivering its MyoPro® powered braces in states that are now allowing such interactions. As a result, Myomo expects revenue for the second quarter of 2020 to be in the range of $0.6 million to $0.7 million.
Jun 15, 2020 08:00 am ET
Myomo® Uses Telehealth Techniques to Conduct Safe Patient Screenings
Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today reported the success of its initiative to conduct safe patient screenings remotely using telehealth technologies.
May 14, 2020 04:05 pm ET
Myomo Reports 2020 First Quarter Financial Results
Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced financial results for the first quarter ended March 31, 2020.
May 12, 2020 04:05 pm ET
Myomo to Report First Quarter Financial Results on May 14, 2020
Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper limb paralysis, today announced that it will report financial results for the first quarter ended March 31, 2020 on Thursday, May 14, 2020 after the market close.
May 01, 2020 10:45 am ET
Thinking about buying stock in Myomo, Microvision, Akorn Inc, Callon Petroleum, or Recon Technology?
NEW YORK, May 1, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for MYO, MVIS, AKRX, CPE, and RCON.
Apr 08, 2020 08:30 am ET
Myomo Reports Accelerating Growth in MyoPro Pipeline and Record Backlog in the First Quarter of 2020, Provides Update on the Business Impact of COVID-19
Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today reported its pipeline of MyoPro candidates continued to grow during the first quarter of 2020, with more than 700 candidates awaiting insurance reimbursement authorization as of March 31, 2020. This compares with 594 candidates as of December 31, 2019. In addition, the backlog of authorized units increased from 53 at the beginning of 2020 to 80 units as of March 31, 2020.
Mar 18, 2020 08:30 am ET
Myomo, Inc., to Present at the New York City based Investor Summit on March 25th-26th
NEW YORK, NY / ACCESSWIRE / March 18, 2020 / Myomo, Inc. (NYSE American:MYO) - A wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, will be presenting at this year's Spring Investor Summit on March 25th-26th.
Mar 12, 2020 04:05 pm ET
Myomo Reports 2019 Fourth Quarter and Full Year Financial Results Featuring Record Revenue and Gross Margins
Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced financial results for the fourth quarter and year ended December 31, 2019.
Mar 05, 2020 04:05 pm ET
Myomo to Report Fourth Quarter and Full Year 2019 Results on March 12, 2020
Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper limb paralysis, today announced that it will report financial results for the fourth quarter and year ended December 31, 2019 on Thursday, March 12, 2020 after the market close.
Feb 19, 2020 04:05 pm ET
Myomo Announces Closing of Public Offering
Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”) a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper limb paralysis, today announced the closing of its previously announced underwritten public offering of 2,143,000 shares of common stock or common stock equivalents (which included pre-funded warrants to purchase shares of common stock in lieu of shares of common stock) and 2,143,000 investor warrants to purchase one share of common stock at a combined offering price of $7.00. Gross proceeds from the offeri
Feb 19, 2020 08:00 am ET
Myomo® Signs Nationwide Payer Network Agreement with HOMELINK
Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper limb paralysis, today announced that it has signed an agreement with HOMELINK which will enable Myomo to process out-of-network claims for its MyoPro powered orthosis with the 1,200 payers in HOMELINK’s network.
Feb 11, 2020 08:59 am ET
Myomo Announces Pricing of Public Offering
Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”) a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper limb paralysis, today announced the pricing of an underwritten public offering of 2,143,000 shares of common stock or common stock equivalents (which includes pre-funded warrants to purchase shares of common stock in lieu of shares of common stock) and investor warrants to purchase up to an aggregate of 2,143,000 shares of common stock. Each share of common stock (or pre-funded warrant in lieu thereof) is b
Feb 06, 2020 04:05 pm ET
Myomo Reports Preliminary Fourth Quarter and Full Year 2019 Results
Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper limb paralysis, today announced preliminary financial and operational results for the fourth quarter and fiscal year ended December 31, 2019.
Feb 05, 2020 12:23 pm ET
Myomo Not Aware of Any Developments to Account for Stock Volatility
Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper limb paralysis, today announced that it is unaware of any developments concerning the business of the Company that could account for the recent trading volatility of the Company’s common stock. The Company's management believes it is prudent to advise the market of this given recent fluctuations of its stock price.
Feb 03, 2020 04:05 pm ET
MyoPro Approved for Reimbursement by German Statutory Health Insurance
Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper limb paralysis, today announced that Statutory Health Insurance in Germany has approved MyoPro for patients on a case by case basis. A major German health insurer, BARMER, with 9 million covered lives, is covering the cost of the MyoPro provided through certified orthotics and prosthetics clinics in Germany. The first patient covered by BARMER has a paralyzed arm caused by a brachial plexus injury sustaine
Jan 30, 2020 02:30 pm ET
Myomo Announces One-for-Thirty Reverse Stock Split of its Common Stock
Myomo, Inc. (NYSE American: MYO), a commercial stage medical robotics company that offers expanded mobility for those suffering from neurological disorders and upper limb paralysis, today announced following approval of a reverse stock split range and authorized share reduction by stockholders at a special meeting of stockholders earlier today, Myomo’s Board of Directors determined to effect a reverse stock split of Myomo’s common stock at a ratio of one-for-thirty. The applicable Certificate of Amendment to the Company’s Eighth Amended and Restated Certificate of Incorporation, as amended, wa
Dec 16, 2019 08:00 am ET
Myomo Announces Partnership with Hobbs Rehabilitation for UK
Myomo®, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper limb paralysis, today announced that it has formed a partnership with Hobbs Rehabilitation to provide a range of services to support MyoPro® users in the UK. Hobbs neurological physiotherapists and occupational therapists will work with patients using the Myomo family of myoelectric orthotics and have already been using Myomo devices to treat patients with upper limb paralysis as par
Nov 12, 2019 04:05 pm ET
Myomo Reports Third Quarter 2019 Results
Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper limb paralysis, today announced its financial results for the third quarter ended September 30, 2019.
Nov 05, 2019 04:05 pm ET
Myomo to Report Third Quarter 2019 Results on November 12, 2019
Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper limb paralysis, today announced that it will release its financial results for the third quarter ended September 30, 2019 on Tuesday, November 12, 2019, after the market close.
Oct 23, 2019 04:05 pm ET
Myomo Closes $3M Term Loan
Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper limb paralysis, today announced that it has entered into a term loan agreement with Chicago Venture Partners (CVP) for $3 million. Myomo expects to use the proceeds to continue to grow the company’s pipeline of qualified MyoPro candidates, introduce the new pediatric version of its MyoPro orthosis, and for general corporate purposes.
Oct 11, 2019 04:05 pm ET
Myomo Announces Departure of Steve Sanghi from Board of Directors
Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper limb paralysis, today announced the resignation of Steve Sanghi from its Board of Directors to focus on his duties as CEO and Board Chairman of Microchip Technology Inc. He will continue to serve as an advisor to Myomo and remain a personal investor in the company.
Aug 21, 2019 08:03 am ET
Myomo Announces Technology Licensing Program for International Markets
Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper limb paralysis, today announced that it has launched a business development program to bring its proprietary MyoPro orthotic product line to a greater number of country markets outside of the United States. The company will pursue technology licensing arrangements with international partners that can manufacture and distribute the MyoPro products to rehabilitation hospitals and patients in their home marke
Aug 08, 2019 04:05 pm ET
Myomo Reports Second Quarter 2019 Results
Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper limb paralysis, today announced its financial results for the second quarter ended June 30, 2019.
Jul 25, 2019 08:00 am ET
United Brachial Plexus Network’s Annual Camp Features MyoPro® Adolescent Patients
Myomo®, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper limb paralysis, was recently a featured presenter at the United Brachial Plexus Network’s Camp UBPN, a worldwide initiative striving to inform and unite patients affecte
Jul 17, 2019 08:00 am ET
Myomo®'s International Distribution Partners Launch Patient Screening Days
Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper limb paralysis, announces that its international distributors in six countries are adopting the marketing model used successfully in the U.S. of introducing the MyoPro® powered orthosis to candidates through screening days.
Jun 17, 2019 08:00 am ET
Myomo Announces First Insurance Reimbursements in European Markets
Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper limb paralysis, announced today that its Orthotics and Prosthetics (O&P) distribution partners in Germany and Denmark have successfully obtained their first reimbursement decisions by insurance payers for the MyoPro orthosis. In addition, these O&P providers, along with other certified firms in the UK and Italy, have a growing number of MyoPro units in the r
May 23, 2019 08:05 am ET
Myomo® Announces Participation in Beijing Trade Show
Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper limb paralysis, announces its participation in the China International Fair for Trade in Services, to be held in Beijing from May 28-31, 2019. Myomo will participate in this event together with Beijing Ryzur Medical Investment Co., Ltd. (Ryzur Medical), a growing medical device manufacturer based in Beijing.
May 13, 2019 07:00 am ET
Myomo Reports First Quarter 2019 Results
Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper limb paralysis, today announced its financial results for the first quarter ended March 31, 2019.
May 07, 2019 08:00 am ET
Myomo to Report First Quarter 2019 Results on May 13, 2019
Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper limb paralysis, today announced that it will release its financial results for the first quarter ended March 31, 2019 on Monday, May 13, 2019, before the US markets open.
May 01, 2019 08:00 am ET
Myomo® Announces New Distribution Agreement for Australia / New Zealand
Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper limb paralysis, today announced that it has signed an agreement with NeuroMuscular Orthotics Pty Ltd (NMO) with the goal of offering MyoPro across Australia and New Zealand.
Apr 16, 2019 08:00 am ET
Myomo® Announces New Sales and Service Agreement for Chile
Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper limb paralysis, today announced that it has signed an agreement with Tecnoplanta Orthopedic Laboratory with the goal of offering MyoPro in Chile.
Apr 15, 2019 07:45 am ET
Report: Developing Opportunities within Navient, Avis Budget Group, ViewRay, Apollo Commercial Real Estate Finance, West Pharmaceutical Services, and Myomo — Future Expectations, Projections Moving in
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Navient Corporation (NASDAQ:NAVI), Avis Budget Group, Inc....
Mar 18, 2019 08:00 am ET
Myomo® Announces New Sales and Service Agreement for Italy
Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper limb paralysis, today announced that it has signed an agreement with Progettiamo Autonomia Robotics (PAR) with the goal of offering MyoPro in Italy. PAR is a unit of Progettiamo Autonomia, headquartered in Reggio Emilia, Italy, with 17 offices nationwide.
Mar 15, 2019 04:05 pm ET
Myomo Makes NYSE American Section 610(b) Public Announcement
Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper limb paralysis, today announced that, as previously disclosed in its Annual Report on Form 10-K for the year ended December 31, 2018 filed on March 12, 2019 with the Securities and Exchange Commission, the audited financial statements for the year ended December 31, 2018 included in the 10-K contained an audit opinion from its independent registered public a
Mar 11, 2019 08:00 am ET
Myomo Announces Participation at Two Upcoming Investor Conferences
Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper limb paralysis, today announced that Chairman and Chief Executive Officer Paul R. Gudonis and Chief Financial Officer David Henry will be presenting, as well as meeting with investors, at two upcoming investor conferences. Details for the two conferences are:
Mar 07, 2019 04:05 pm ET
Myomo Reports Fourth Quarter and Year End 2018 Results
Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper limb paralysis, today announced its financial results for the fourth quarter and year ended December 31, 2018.
Feb 28, 2019 04:05 pm ET
Myomo to Report Fourth Quarter and Year End 2018 Results on March 7, 2019
Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper limb paralysis, today announced that it will release its financial results for the fourth quarter and year ended December 31, 2018 on Thursday, March 7, 2019, after the US markets close.
Feb 20, 2019 08:00 am ET
Investor Expectations to Drive Momentum within Enphase Energy, EQT, BorgWarner, Ringcentral, Chanticleer, and Myomo — Discovering Underlying Factors of Influence
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Enphase Energy, Inc. (NASDAQ:ENPH), EQT Corporation (NYSE:EQT),...
Feb 12, 2019 04:05 pm ET
Myomo, Inc. Announces Closing of Public Offering and Full Exercise of Over-Allotment Option
Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper limb paralysis, today has closed its previously announced underwritten public offering of 3,950,000 shares of common stock at an offering price of $1.40 per share. In connection with the offering, the underwriter exercised in full its over-allotment option to purchase an additional 592,500 shares of common stock at the public offering price, less underwritin
Feb 08, 2019 08:30 am ET
Myomo, Inc. Prices Public Offering of Common Stock
Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper limb paralysis, today announced the pricing of its previously announced underwritten public offering of 3,950,000 shares of its common stock at an offering price of $1.40 per share. In addition, Myomo has granted the underwriter a 45-day option to purchase up to an additional 592,500 shares to cover over-allotments, if any. All of the common shares are being
Feb 07, 2019 04:05 pm ET
Myomo, Inc. Announces Proposed Public Offering of Common Stock
Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper limb paralysis, today announced that it is proposing to offer and sell, subject to market conditions, shares of its common stock in an underwritten public offering. Myomo expects to grant the underwriter a 45-day option to purchase up to an additional 15% of the shares of common stock offered in the public offering to cover over-allotments, if any. All of th
Feb 06, 2019 08:00 am ET
Myomo Announces CFO Succession
Myomo Inc. (NYSE American MYO) (“Myomo,” or the “Company”), a wearable medical robotics company that offers expanded mobility for those suffering from neurological disorders and upper limb paralysis, today announced that Ralph A. Goldwasser, its Chief Financial Officer, is retiring effective as of February 18, 2019. Mr. Goldwasser, age 71, will provide transitional services to the Company for an expected three-month term under a transition and consulting agreement.
Jan 17, 2019 08:00 am ET
Myomo® to Present at Noble Capital Markets’ 15th Annual Investor Conference
Myomo, Inc. (NYSE American: MYO) (“Myomo,” or the “Company”), a wearable medical robotics company, today announced that it will be presenting at NobleCon15 - Noble Capital Markets’ Fifteenth Annual Investor Conference at the W Hotel, Fort Lauderdale, Florida on Monday, January 28th at 10:30 AM EST - Studio 3. Chairman and Chief Executive Officer Paul R. Gudonis and Chief Financial Officer Ralph A. Goldwasser will be presenting, as well as meeting with investors.
Nov 14, 2018 08:05 am ET
Myomo Announces First Adolescent Patients to be Fitted with MyoPro
Myomo, Inc., a wearable medical robotics company, has achieved recent momentum fitting and delivering MyoPro to adolescent users. Approved to assist young adults suffering from any disease or injury leaving them with a paralyzed or weakened arm, MyoPro is restoring motion and functionality to adolescents with conditions such as cerebral palsy, brachial plexus injury, and more. MyoPro is now being tested on Acute Flaccid Myelitis ("AFM") patients with promising results.
Nov 07, 2018 08:10 am ET
Analysis: Positioning to Benefit within Noble Energy, Myomo, Realty Income, Cross Country Healthcare, Ares Management, and Archrock — Research Highlights Growth, Revenue, and Consolidated Results
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Noble Energy Inc. (NYSE:NBL), Myomo, Inc. (NYSE:MYO), Realty Income...
Nov 06, 2018 12:54 pm ET
Myomo® Receives Medicare Codes
Myomo, Inc. (NYSE American: MYO) (“Myomo,” or the “Company”), a wearable medical robotics company, announces that the Centers for Medicare & Medicaid Services ("CMS") has published two new codes pursuant to the Company’s application for Healthcare Common Procedure Coding System (HCPCS) “L” codes. Myomo had filed its application in December 2017 to have CMS establish two new Level II HCPCS codes and received a favorable preliminary decision in May.
Nov 05, 2018 04:05 pm ET
Myomo Announces Third Quarter 2018 Financial Results
Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper limb paralysis, today reports its financial results for the third quarter ended September 30, 2018.
Oct 30, 2018 11:20 am ET
Myomo to Report Third Quarter 2018 Results on November 5, 2018
Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company, today announced that it will release its financial results for the third quarter 2018 on Monday, November 5, 2018, after the US markets close.
Oct 16, 2018 07:36 am ET
Report: Developing Opportunities within The Ensign Group, Forterra, Inc., Audentes Therapeutics, Assembly Biosciences, Capital Senior Living, and Myomo — Future Expectations, Projections Moving into 2
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of The Ensign Group, Inc. (NASDAQ:ENSG), Forterra, Inc. (NASDAQ:FRTA),...
Sep 18, 2018 08:00 am ET
Myomo to Present at The MicroCap Conference
CAMBRIDGE, MA. / ACCESSWIRE / September 18, 2018 / Myomo, Inc. (NYSE American: MYO) ("Myomo" or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper limb paralysis, today announced that it will be presenting at The MicroCap Conference on Monday, October 1st at 11:00 AM EDT, Track 1, Essex House in New York City. Chairman and Chief Executive Officer Paul R. Gudonis and Chief Financial Officer Ralph A. Goldwasser will be presenting, as well as meeting with investors.
Sep 12, 2018 08:05 am ET
Myomo Announces Continued Momentum Across Europe
Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company, today announced continued momentum across Europe with the appointment of John Frijters as Business Development Manager for EU, a distributor agreement with Bandagist Jan Nielsen to deliver MyoPro to patients across Denmark and the first scree
Aug 16, 2018 07:40 am ET
Analysis: Positioning to Benefit within Quanex Building Products, Molecular Templates, Atara Biotherapeutics, Forward Industries, Apollo Endosurgery, and Myomo — Research Highlights Growth, Revenue, a
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Quanex Building Products Corporation (NYSE:NX), Molecular Templates Inc....
Aug 07, 2018 04:05 pm ET
Myomo Announces Second Quarter 2018 Financial Results
Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper limb paralysis, today reports its financial results for the second quarter ended June 30, 2018.
Jul 31, 2018 08:00 am ET
Myomo to Report Second Quarter 2018 Results on August 7, 2018
Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company, today announced that it will release its financial results for the second quarter 2018 on Tuesday, August 7, 2018, after the US markets close.
Jul 09, 2018 08:00 am ET
Myomo Appoints Micah Mitchell as Chief Commercial Officer
Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company, announced today that Micah Mitchell is joining the company as chief commercial officer (CCO), a newly created executive role. The addition of a CCO reflects Myomo’s transition from a controlled introduction of its proprietary MyoPro product li
Jun 27, 2018 08:00 am ET
Research Team Presents Promising Preliminary Results from TBI Study Using Myomo’s MyoPro
Researchers from the Northwestern University Prosthetics-Orthotics Center (NUPOC) and the Cleveland VA Medical Center have presented promising preliminary case reports from a clinical trial that evaluates the effects of the MyoPro myoelectric arm orthosis (powered brace) from Myomo on traumatic brain injury (TBI) patients at the Cleveland VA Medical Center.
Jun 06, 2018 08:00 am ET
Myomo Brings MyoPro to Adolescent Patients
Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company, today announced that its MyoPro myoelectric arm orthosis (powered brace) is now available to adolescent patients with paralyzed or weakened arms. MyoPro is the only lightweight wearable device on the market that can help restore substantial fu
May 29, 2018 07:30 am ET
New Research: Key Drivers of Growth for Primo Water, Columbus McKinnon, Dominion Energy Midstream Partners, LP, Monroe Capital, Kimball Electronics, and Myomo — Factors of Influence, Major Initiatives
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Primo Water Corporation (NASDAQ:PRMW), Columbus McKinnon Corporation...
May 24, 2018 08:00 am ET
Myomo Announces MyoPro Availability in 16 New U.S. Locations
Myomo®, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper limb paralysis, today announced agreements with leading orthotics and prosthetics practices to bring MyoPro® availability to 16 new U.S. locations.
May 14, 2018 08:00 am ET
Myomo® Application for Medicare Codes Receives Favorable Preliminary Decision
Myomo, Inc. (NYSE American:MYO) (“Myomo,” or the “Company”), a wearable medical robotics company, announces that the Centers for Medicare & Medicaid Services ("CMS") has published a favorable preliminary decision regarding the Company’s application for Healthcare Common Procedure Coding System (HCPCS) “L” codes. Myomo had filed its application in December 2017 to have CMS establish two new Level II HCPCS codes to describe “microprocessor-controlled, custom fabricated upper extremity braces.”
May 10, 2018 08:00 am ET
Myomo, Inc. Issues May 2018 Shareholder Letter
Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper limb paralysis, today issued a letter to shareholders to give an update on first quarter 2018 and ongoing MyoPro® commercial activities.
May 09, 2018 04:05 pm ET
Myomo Reports First Quarter 2018 Results
Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper limb paralysis, today reports its financial results for the first quarter ended March 31, 2018.
May 03, 2018 08:00 am ET
Myomo to Report First Quarter 2018 Results on May 9, 2018
Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a commercial stage medical robotics company, today announced that it will release its financial results for the first quarter 2018 on Wednesday, May 9, 2018, after the US markets close.
May 02, 2018 08:00 am ET
Myomo Announces Free Screening Days in Over 20 Cities Nationwide
Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a commercial stage medical robotics company, announces a nationwide program of free screening days to be held in collaboration with its Centers of Excellence, other orthotics and prosthetics practices and its rehabilitation therapy partners.
Apr 04, 2018 07:35 am ET
Recent Analysis Shows Myomo, Shiloh Industries, Regal Beloit, Teledyne Technologies, Envestnet, and Independent Bank Market Influences — Renewed Outlook, Key Drivers of Growth
NEW YORK, April 04, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Myomo, Inc. (NYSE:MYO), Shiloh Industries, Inc....
Mar 16, 2018 04:05 pm ET
UPDATE - Myomo Reports Fourth Quarter and Year End 2017 Results
Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a commercial stage medical robotics company, today announced that it is updating its previous release that was made on March 7, 2018 to incorporate certain disclosures that are required under the NYSE AMERICAN Company Guide Sections 401(h) and 610(b). Included below are these additional disclosures along with the previously disclosed financial results for the fourth quarter and year end December 31, 2017. This announcement does not represent any change or amendment to the Compan
Mar 12, 2018 08:00 am ET
Myomo Welcomes 13 New Center of Excellence Locations
Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a commercial stage medical robotics company, today announced the addition of three new orthotics and prosthetics (O&P) practices and 13 new locations to its MyoPro Center of Excellence (CoE) program, which recognizes top O&P practices that support the MyoPro line of powered orthoses. The addition of the practices brings the total number of CoE locations across the United States to 46.
Mar 09, 2018 08:00 am ET
Myomo Announces Participation at Upcoming Investor and Partnering Conferences
Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a commercial stage medical robotics company, today announced that Chairman and Chief Executive Officer Paul R. Gudonis will be participating at two upcoming investor, partnering and collaboration conferences. The details for the two conferences are:
Mar 08, 2018 08:00 am ET
Myomo, Inc. Issues March 2018 Shareholder Letter
Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a commercial stage medical robotics company, today issued a letter to shareholders to give an update on fourth quarter 2017 and ongoing MyoPro® commercial activities.
Mar 07, 2018 04:05 pm ET
Myomo Reports Fourth Quarter and Year End 2017 Results
Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a commercial stage medical robotics company, today reports its financial results for the fourth quarter and year end December 31, 2017.
Mar 05, 2018 08:31 am ET
Thinking about buying or selling stock or options in Boeing, Chemours Co, Myomo Inc, Netflix and Visa?
CHICAGO, March 5, 2018 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for BA, CC, MYO, NFLX, and V.
Mar 05, 2018 08:00 am ET
Myomo to Present at the 30th Annual ROTH Conference
Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a commercial stage medical robotics company, today announced that it will be presenting at the 30th Annual ROTH Conference in Dana Point, CA on Monday, March 12th at 9:00 AM PT, Blue - Salon 2. Chairman and Chief Executive Officer Paul R. Gudonis will be presenting, as well as meeting with investors.
Feb 28, 2018 08:00 am ET
Myomo to Report Fourth Quarter and Year End 2017 Results on March 7, 2018
Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a commercial stage medical robotics company, today announced that it will release its financial results for the fourth quarter and year end December 31, 2017 results on Wednesday, March 7, 2018, after the US markets close.
Feb 14, 2018 08:00 am ET
Myomo and GRE to Conduct Screening Days in Ohio and Detroit
Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a commercial stage medical robotics company, and Geauga Rehabilitation Engineering (GRE) have announced a series of free screening days to be held at the offices of GRE and its local partners near Cleveland, Detroit, Columbus and Cincinnati.
Feb 06, 2018 07:30 pm ET
Johnson Fistel, Announces Investigations of ADOMANI, Inc., ShiftPixy, Inc., Arcimoto, Inc., Myomo, Inc., FAT Brands Inc., Level Brands, Inc. and Chicken Soup for the Soul Entertainment, Inc.; Investor
SAN DIEGO, Feb. 6, 2018 /PRNewswire/ -- Shareholder Rights Law Firm Johnson Fistel, LLP is investigating potential claims against ADOMANI, Inc., ShiftPixy, Inc., Arcimoto, Inc., Myomo, Inc., FAT Brands Inc., Level Brands, Inc., and Chicken Soup for the Soul Entertainment, Inc., as detailed below:
Feb 06, 2018 08:10 am ET
New Research: Key Drivers of Growth for Tallgrass Energy GP, LP, Lithia Motors, Akcea Therapeutics, Meridian Bioscience, Myomo, and Liberty Media — Factors of Influence, Major Initiatives and Sustaine
NEW YORK, Feb. 06, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Tallgrass Energy GP, LP (NYSE:TEGP), Lithia...
Jan 26, 2018 08:31 am ET
Stock and options trades released for AbbVie, Alibaba, Intel, Myomo Inc and Starbucks
CHICAGO, Jan. 26, 2018 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ABBV, BABA, INTC, MYO, and SBUX.
Jan 24, 2018 08:00 am ET
Myomo Completes Repayment of Loan to the Massachusetts Life Sciences Center
Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a commercial stage medical robotics company, and the Massachusetts Life Sciences Center (MLSC) today celebrated Myomo’s repayment of a $750,000 accelerator loan provided by the MLSC in 2011. Myomo completed repayment of the loan, which totaled $1,350,618 with interest, on December 13, 2017. Myomo Chairman and CEO Paul R. Gudonis presented a ceremonial check to Travis McCready, President and CEO of MLSC, during a ceremony at Myomo’s headquarters in the Cambridge Innovation Center.
Jan 16, 2018 08:00 am ET
Myomo to Present at Noble Capital Markets’ 14th Annual Investor Conference
Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a commercial stage medical robotics company, today announced that it will be presenting at NobleCon14 - Noble Capital Markets’ Fourteenth Annual Investor Conference at the W Hotel, Fort Lauderdale, Florida on Monday, January 29th at 11:00 AM EST - Studio 4. Chairman and Chief Executive Officer Paul R. Gudonis will be presenting, as well as meeting with investors.
Dec 06, 2017 04:30 pm ET
Myomo, Inc. Announces Full Exercise of Underwriter’s Over-Allotment Option in Follow-On Public Offering
Myomo, Inc. (NYSE American: MYO), a commercial stage medical robotics company, today announced that Roth Capital Partners, the underwriter of Myomo’s follow-on offering, exercised in full its option to purchase 626,250 shares of common stock and accompanying warrants to purchase 626,250 shares of common stock, at a combined price to the public of $2.40 per share of common stock and accompanying warrant, for gross proceeds of approximately $1.5 million. After giving effect to the full exercise of the over-allotment, the Company sold an aggregate
Nov 30, 2017 08:31 am ET
Myomo, Inc. Announces Pricing of Public Offering
Myomo, Inc. (NYSE American: MYO), a commercial stage medical robotics company, today announced that it has priced an underwritten public offering of 4,175,000 shares of its common stock and accompanying warrants to purchase 4,175,000 shares of common stock. Each share of common stock is being sold together with one warrant to purchase one share of common stock, at a combined price to the public of $2.40 per share of common stock and accompanying warrant, for gross proceeds of approximately $10.0 million. The warrants have an exercise price of
Nov 29, 2017 08:00 am ET
Myomo Expands MyoPro® Centers of Excellence Program
Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a commercial stage medical robotics company, today announced the addition of six new orthotics and prosthetics (O&P) locations to its Center of Excellence (CoE) program, which recognizes top O&P practices that support the MyoPro line of powered orthoses. MyoPro is currently the only lightweight wearable device that can help restore function in the paralyzed or weakened arms and hands of individuals who have suffered a stroke, brachial plexus injury (BPI) or other neuromuscular disabili
Nov 28, 2017 08:00 am ET
Myomo, Inc. to Present at the 10th Annual LD Micro Main Event
Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a commercial stage medical robotics company, today announced that it will be presenting at the 10th annual LD Micro Main Event on Tuesday, December 5th at 9:30 AM PST / 12:30 PM EST at the Luxe Sunset Boulevard Hotel in Los Angeles, CA. Chairman and Chief Executive Officer Paul R. Gudonis will be presenting, as well as meeting with investors.
Nov 13, 2017 04:05 pm ET
Myomo, Inc. Files Registration Statement for Proposed Follow-On Offering
Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a commercial stage medical robotics company, announced the filing of a registration statement with the U.S. Securities and Exchange Commission (SEC) relating to a proposed underwritten follow-on public offering of shares of its common stock and accompanying warrants to purchase common stock.
Nov 07, 2017 08:00 am ET
Myomo, Inc. Issues November 2017 Shareholder Letter
Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a commercial stage medical robotics company, today issued a letter to shareholders to give an update on third quarter 2017 and ongoing MyoPro® commercial activities.
Nov 06, 2017 04:13 pm ET
Myomo, Inc. Reports Third Quarter 2017 Results
Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a commercial stage medical robotics company, today reports its financial results for the three and nine months ended September 30, 2017.
Nov 03, 2017 08:00 am ET
Myomo Enters Canadian Market
Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a commercial stage medical robotics company, today announced that its Application for a Canadian Medical Device License has been approved by Health Canada. With the license, Myomo and its distribution partner, Ottobock, are now entering the Canadian market for commercial sale of the MyoPro myolelectric arm orthosis (powered brace).
Oct 30, 2017 08:00 am ET
Myomo, Inc. to Report Third Quarter 2017 Results on November 6, 2017
Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a commercial stage medical robotics company, today announced that it will release its unaudited financial results for the quarter ended September 30, 2017 on Monday, November 6, 2017, after the US markets close.
Oct 17, 2017 08:00 am ET
Myomo, Inc. Launches Awareness Program for Veterans of the U.S. Armed Forces
Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a commercial stage medical device company, today announced the launch of MyoPro For Veterans, a strategic awareness program that broadens accessibility of MyoPro powered upper limb orthotics (arm brace) to the many veterans of the U.S. Armed Forces that could potentially benefit from the technology, restoring function to weakened or paralyzed upper limbs.

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.